Show simple item record

dc.contributor.authorJorgensen, Sarah C. J.
dc.contributor.authorTrinh, Trang D.
dc.contributor.authorZasowski, Evan J.
dc.contributor.authorLagnf, Abdalhamid M.
dc.contributor.authorBhatia, Sahil
dc.contributor.authorMelvin, Sarah M.
dc.contributor.authorSimon, Samuel P.
dc.contributor.authorRosenberg, Joshua R.
dc.contributor.authorSteed, Molly E.
dc.contributor.authorEstrada, Sandra J.
dc.contributor.authorMorrisette, Taylor
dc.contributor.authorDavis, Susan L.
dc.contributor.authorRybak, Michael J.
dc.date.accessioned2022-09-20T18:58:06Z
dc.date.available2022-09-20T18:58:06Z
dc.date.issued2020-02-22
dc.identifier.citationJorgensen, S.C.J., Trinh, T.D., Zasowski, E.J. et al. Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam. Infect Dis Ther 9, 291–304 (2020). https://doi.org/10.1007/s40121-020-00288-4en_US
dc.identifier.urihttp://hdl.handle.net/1808/33553
dc.description.abstractBackground The aim of this study was to evaluate the predictive performance of the INCREMENT-CPE (ICS), Pitt bacteremia score (PBS) and qPitt for mortality among patients treated with ceftazidime–avibactam for carbapenem-resistant Enterobacteriaceae (CRE) infections.

Methods Retrospective, multicenter, cohort study of patients with CRE infections treated with ceftazidime–avibactam between 2015 and 2019. The primary outcome was 30-day all-cause mortality. Predictive performance was determined by assessing discrimination, calibration and precision.

Results In total, 109 patients were included. Thirty-day mortality occurred in 18 (16.5%) patients. There were no significant differences in discrimination of the three scores [area under the curve (AUC) ICS 0.7039, 95% CI 0.5848–0.8230, PBS 0.6893, 95% CI 0.5709–0.8076, and qPitt 0.6847, 95% CI 0.5671–0.8023; P > 0.05 all pairwise comparisons]. All scores showed adequate calibration and precision. When dichotomized at the optimal cut-points of 11, 3, and 2 for the ICS, PBS, and qPitt, respectively, all scores had NPV > 90% at the expense of low PPV. Patients in the high-risk groups had a relative risk for mortality of 3.184 (95% CI 1.35–8.930), 3.068 (95% CI 1.094–8.606), and 2.850 (95% CI 1.016–7.994) for the dichotomized ICS, PBS, and qPitt, scores respectively. Treatment-related variables (early active antibiotic therapy, combination antibiotics and renal ceftazidime–avibactam dose adjustment) were not associated with mortality after controlling for the risk scores.

Conclusions In patients treated with ceftazidime–avibactam for CRE infections, mortality risk scores demonstrated variable performance. Modifications to scoring systems to more accurately predict outcomes in the era of novel antibiotics are warranted.
en_US
dc.publisherSpringeren_US
dc.rightsCopyright The Author(s) 2020. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.en_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en_US
dc.subjectCarbapenem-resistant Enterobacteriaceaeen_US
dc.subjectCeftazidime–avibactamen_US
dc.subjectINCREMENT-CPEen_US
dc.subjectPitt bacteremiaen_US
dc.titleEvaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactamen_US
dc.typeArticleen_US
kusw.kuauthorSteed, Molly E.
kusw.kudepartmentPharmacy Practiceen_US
dc.identifier.doi10.1007/s40121-020-00288-4en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Copyright The Author(s) 2020. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Except where otherwise noted, this item's license is described as: Copyright The Author(s) 2020. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.